CN102552879B - 肺表面活性提取物与肺表面活性物质相关蛋白a的组合物、制备方法及其制药用途 - Google Patents
肺表面活性提取物与肺表面活性物质相关蛋白a的组合物、制备方法及其制药用途 Download PDFInfo
- Publication number
- CN102552879B CN102552879B CN2012100678966A CN201210067896A CN102552879B CN 102552879 B CN102552879 B CN 102552879B CN 2012100678966 A CN2012100678966 A CN 2012100678966A CN 201210067896 A CN201210067896 A CN 201210067896A CN 102552879 B CN102552879 B CN 102552879B
- Authority
- CN
- China
- Prior art keywords
- extract
- preparation
- solution
- lung
- surface active
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010007100 Pulmonary Surfactant-Associated Protein A Proteins 0.000 title claims abstract description 110
- 239000000284 extract Substances 0.000 title claims abstract description 81
- 238000002360 preparation method Methods 0.000 title claims abstract description 40
- 239000000203 mixture Substances 0.000 title claims abstract description 36
- 102000007615 Pulmonary Surfactant-Associated Protein A Human genes 0.000 title abstract description 100
- 239000003580 lung surfactant Substances 0.000 title abstract description 13
- 230000000694 effects Effects 0.000 claims abstract description 41
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 27
- 238000000034 method Methods 0.000 claims abstract description 26
- 238000001914 filtration Methods 0.000 claims abstract description 15
- 239000003960 organic solvent Substances 0.000 claims abstract description 11
- 239000002699 waste material Substances 0.000 claims abstract description 11
- 238000000746 purification Methods 0.000 claims abstract description 10
- 239000000919 ceramic Substances 0.000 claims abstract description 8
- 210000004072 lung Anatomy 0.000 claims description 61
- 239000000243 solution Substances 0.000 claims description 47
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 35
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical group ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 24
- 238000001556 precipitation Methods 0.000 claims description 20
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 19
- 239000007788 liquid Substances 0.000 claims description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical group CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 14
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 13
- 239000012530 fluid Substances 0.000 claims description 13
- 239000011780 sodium chloride Substances 0.000 claims description 13
- 241000283690 Bos taurus Species 0.000 claims description 12
- 239000003480 eluent Substances 0.000 claims description 12
- 238000000605 extraction Methods 0.000 claims description 12
- 238000001291 vacuum drying Methods 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 11
- 239000000725 suspension Substances 0.000 claims description 11
- 238000004108 freeze drying Methods 0.000 claims description 10
- 230000008719 thickening Effects 0.000 claims description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 239000006228 supernatant Substances 0.000 claims description 9
- 239000011259 mixed solution Substances 0.000 claims description 8
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 7
- 239000001110 calcium chloride Substances 0.000 claims description 7
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 7
- 238000005516 engineering process Methods 0.000 claims description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 claims description 6
- BQFCCCIRTOLPEF-UHFFFAOYSA-N chembl1976978 Chemical compound CC1=CC=CC=C1N=NC1=C(O)C=CC2=CC=CC=C12 BQFCCCIRTOLPEF-UHFFFAOYSA-N 0.000 claims description 6
- 238000000703 high-speed centrifugation Methods 0.000 claims description 6
- 238000000108 ultra-filtration Methods 0.000 claims description 6
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical group CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 claims description 5
- 229920000936 Agarose Polymers 0.000 claims description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- 239000007983 Tris buffer Substances 0.000 claims description 4
- 238000011097 chromatography purification Methods 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000002244 precipitate Substances 0.000 claims description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 3
- 239000006184 cosolvent Substances 0.000 claims description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 238000000194 supercritical-fluid extraction Methods 0.000 claims description 3
- 238000010266 Sephadex chromatography Methods 0.000 claims description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000000872 buffer Substances 0.000 claims description 2
- 238000000105 evaporative light scattering detection Methods 0.000 claims description 2
- 230000007935 neutral effect Effects 0.000 claims description 2
- 239000003208 petroleum Substances 0.000 claims description 2
- 239000002798 polar solvent Substances 0.000 claims description 2
- 102100027773 Pulmonary surfactant-associated protein A2 Human genes 0.000 claims 10
- 239000011324 bead Substances 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 abstract description 8
- 208000004852 Lung Injury Diseases 0.000 abstract description 8
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 abstract description 8
- 206010069363 Traumatic lung injury Diseases 0.000 abstract description 8
- 201000000028 adult respiratory distress syndrome Diseases 0.000 abstract description 8
- 231100000515 lung injury Toxicity 0.000 abstract description 8
- 230000004064 dysfunction Effects 0.000 abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 238000004519 manufacturing process Methods 0.000 abstract description 6
- 201000010099 disease Diseases 0.000 abstract description 5
- 230000005764 inhibitory process Effects 0.000 abstract description 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract description 3
- 201000005085 Meconium Aspiration Syndrome Diseases 0.000 abstract description 3
- 206010035664 Pneumonia Diseases 0.000 abstract description 3
- 206010006475 bronchopulmonary dysplasia Diseases 0.000 abstract description 3
- 238000000638 solvent extraction Methods 0.000 abstract description 3
- 230000001775 anti-pathogenic effect Effects 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 230000002685 pulmonary effect Effects 0.000 abstract 1
- 239000002158 endotoxin Substances 0.000 description 15
- 229920006008 lipopolysaccharide Polymers 0.000 description 15
- 238000012360 testing method Methods 0.000 description 12
- 102000008946 Fibrinogen Human genes 0.000 description 10
- 108010049003 Fibrinogen Proteins 0.000 description 10
- 229940012952 fibrinogen Drugs 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 9
- 241000700159 Rattus Species 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 208000014674 injury Diseases 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 241000282894 Sus scrofa domesticus Species 0.000 description 5
- 229940092456 curosurf Drugs 0.000 description 5
- 229920005654 Sephadex Polymers 0.000 description 4
- 239000012507 Sephadex™ Substances 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 230000008485 antagonism Effects 0.000 description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
- 206010037423 Pulmonary oedema Diseases 0.000 description 3
- 241000282898 Sus scrofa Species 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 229940067606 lecithin Drugs 0.000 description 3
- 239000000787 lecithin Substances 0.000 description 3
- 235000010445 lecithin Nutrition 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 208000032571 Infant acute respiratory distress syndrome Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028974 Neonatal respiratory distress syndrome Diseases 0.000 description 2
- 102000007620 Pulmonary Surfactant-Associated Protein C Human genes 0.000 description 2
- 108010007125 Pulmonary Surfactant-Associated Protein C Proteins 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000002612 cardiopulmonary effect Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 238000001085 differential centrifugation Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000013010 irrigating solution Substances 0.000 description 2
- 201000002652 newborn respiratory distress syndrome Diseases 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 208000005333 pulmonary edema Diseases 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- -1 ultrasonic Substances 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 208000000203 Hyaline Membrane Disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- 208000007123 Pulmonary Atelectasis Diseases 0.000 description 1
- 101000632470 Sus scrofa Pulmonary surfactant-associated protein A Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 210000002588 alveolar type II cell Anatomy 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 102000023852 carbohydrate binding proteins Human genes 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 230000001723 fibrinogenic effect Effects 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 210000003677 hemocyte Anatomy 0.000 description 1
- 229940000351 hemocyte Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 231100000516 lung damage Toxicity 0.000 description 1
- 229940066294 lung surfactant Drugs 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000009325 pulmonary function Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 108010038196 saccharide-binding proteins Proteins 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Landscapes
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
样品 | a | b | C2(2%) | C5(5%) | C10(10%) |
最低表面张力mN/m | 0.82 | 35.58 | 6.88 | 1.05 | 0.89 |
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2012100678966A CN102552879B (zh) | 2012-03-15 | 2012-03-15 | 肺表面活性提取物与肺表面活性物质相关蛋白a的组合物、制备方法及其制药用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2012100678966A CN102552879B (zh) | 2012-03-15 | 2012-03-15 | 肺表面活性提取物与肺表面活性物质相关蛋白a的组合物、制备方法及其制药用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102552879A CN102552879A (zh) | 2012-07-11 |
CN102552879B true CN102552879B (zh) | 2013-11-06 |
Family
ID=46400331
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2012100678966A Active CN102552879B (zh) | 2012-03-15 | 2012-03-15 | 肺表面活性提取物与肺表面活性物质相关蛋白a的组合物、制备方法及其制药用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102552879B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104382942A (zh) * | 2014-11-05 | 2015-03-04 | 烟台东诚药业集团股份有限公司 | 一种猪肺表面活性物质混悬液制备新工艺 |
CN110174456B (zh) * | 2019-06-11 | 2021-09-21 | 华润双鹤药业股份有限公司 | 一种测定肺表面活性物质蛋白的方法及其应用 |
CN114159546B (zh) * | 2021-12-20 | 2024-06-04 | 北京双鹤润创科技有限公司 | 新一代合成肺表面活性物质制剂及其临床应用 |
CN115634199B (zh) * | 2022-10-18 | 2024-05-03 | 杭州汉库医药科技有限公司 | 一种混悬型肺表面活性物质注射液及其制备方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL134880A0 (en) * | 1997-09-05 | 2001-05-20 | Univ Southern Australia | A method of diagnosis |
CA2744940A1 (en) * | 2008-12-10 | 2010-06-17 | Paka Pulmonary Pharmaceuticals, Inc. | Methods and compositions for delivery of medicaments to the lungs |
-
2012
- 2012-03-15 CN CN2012100678966A patent/CN102552879B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN102552879A (zh) | 2012-07-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102552879B (zh) | 肺表面活性提取物与肺表面活性物质相关蛋白a的组合物、制备方法及其制药用途 | |
JP5946830B2 (ja) | マンネンタケ子実体の効果的な分画、抽出方法、用途及び製剤 | |
Poli et al. | Toxicity and pathophysiology of palytoxin congeners after intraperitoneal and aerosol administration in rats | |
CN109825472A (zh) | 一种细胞外囊泡的提取方法及试剂盒 | |
Koukouraki et al. | Antithrombotic properties of Spirulina extracts against platelet-activating factor and thrombin | |
CN109527270A (zh) | 水蛭特异性营养诱导液及天然水蛭素的提取方法 | |
CN108715600A (zh) | 一种促进肠黏膜上皮细胞增殖和迁移的寡肽及其制备方法和应用 | |
CN109369783B (zh) | 一种多肽rdp1及其提纯方法与应用 | |
CN108623677A (zh) | 一种静注人免疫球蛋白的提纯方法 | |
CN107119097A (zh) | 一种桑叶免疫活性肽及其制备方法 | |
CN104655737B (zh) | 基于液质联用检测膜蛋白与配体亲和力的混合物筛选方法 | |
CN102335413B (zh) | 一种具抗β-乳球蛋白过敏效果的乳杆菌完整肽聚糖的制备方法、产品及其应用 | |
CN101012449B (zh) | 淋巴细胞分离液及分离脾脏淋巴细胞的方法 | |
CN104152518A (zh) | 一种肝病辅食型鳕鱼皮胶原蛋白肽的制备方法 | |
CN1891235A (zh) | 一种地龙注射制剂及其制备方法 | |
CN105753975A (zh) | 一种基于疏水柱的乌司他丁纯化方法 | |
CN100465270C (zh) | 沙蚕蛋白酶及其分离提取纯化方法和应用 | |
CN105238772A (zh) | 一种尿激酶分离纯化方法 | |
CN104984739B (zh) | 一种明胶亲和层析介质的制备方法及其应用 | |
CN106432406A (zh) | 一种梅花鹿角盘小分子蛋白单体的制备方法 | |
CN108822228A (zh) | 一种荔枝多糖的快速纯化方法 | |
CN107304413A (zh) | 一种外泌体快速分离和纯化的试剂盒 | |
Tchorzewski et al. | A new lymphocyte transforming factor derived from the lysosomes of polymorphonuclear leucocytes | |
CN107812003A (zh) | Vx‑809在制备治疗进行性家族性肝内胆汁淤积症药物中的应用 | |
CN103396472A (zh) | 一种具有溶栓活性的全蝎提取物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: CHINA RESOURCES DOUBLE-CRANE PHARMACEUTICAL CO., L Free format text: FORMER OWNER: SHUANGHE MODERN MEDICINAL TECHNOLOGY CO LTD, BEIJING Effective date: 20131113 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100121 CHAOYANG, BEIJING TO: 100102 CHAOYANG, BEIJING |
|
TR01 | Transfer of patent right |
Effective date of registration: 20131113 Address after: Two road 100102 Beijing city Chaoyang District Wangjing Lizedong No. 1 Patentee after: CHINA RESOURCES DOUBLE-CRANE PHARMACEUTICAL Co.,Ltd. Address before: 100121 No. 2 Shuangqiao East Road, Beijing, Chaoyang District Patentee before: Beijing Double-crane Pharmaceutical Co.,Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20201130 Address after: 570000 No.2 Yaogu SANHENG Road, Yaogu Industrial Park, Haikou national high tech Zone, Haikou City, Hainan Province Patentee after: Double Crane Pharmaceutical (Hainan) Co.,Ltd. Address before: Two road 100102 Beijing city Chaoyang District Wangjing Lizedong No. 1 Patentee before: CHINA RESOURCES DOUBLE-CRANE PHARMACEUTICAL Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20221012 Address after: 100102 floor 2, building 2, No. 1, lizedong 2nd Road, Chaoyang District, Beijing Patentee after: Beijing Shuanghe runchuang Technology Co.,Ltd. Address before: No. 2, Yaogu Sanheng Road, Yaogu Industrial Park, Haikou National High-tech Zone, Hainan Province, Haikou City, Hainan Province, 570000 Patentee before: Double Crane Pharmaceutical (Hainan) Co.,Ltd. |
|
TR01 | Transfer of patent right |